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sTo the Editor: Amiodarone is used as an antiarrhythmic agent in
patients with pulmonary hypertension, who suffer the double insult of
having an increased susceptibility to arrhythmias as well as being more
likely to suffer cardiovascular compromise as a result of these arrhyth-
mias (1). Other agents, e.g., beta-blockers, may be unsuitable due to
their negative inotropic effect. Thyroid dysfunction is a well-known
side effect of amiodarone, with a prevalence of up to 24% in patients
with acquired heart disease (2). We noted that a disproportionately
igh number of patients with idiopathic pulmonary arterial hyperten-
ion (IPAH) suffered from amiodarone-induced thyroid dysfunction
AITD) with severe consequences. Therefore, we decided to study
miodarone use and thyroid function in pulmonary hypertension.
We examined all IPAH patients diagnosed from 1995 to 2007 (n
120), and identified patients on amiodarone for 3 months (n 
1), and patients who had never been on amiodarone (n  72).
Controls were chosen from patients with chronic thromboembolic
pulmonary hypertension (CTEPH) (n  23) on amiodarone for 3
months; and PAH associated with congenital heart disease (CHD) (n
 12) on amiodarone for 3 months. Three months was chosen as
he minimum, as transient increases in TSH (thyroid-stimulating
ormone) are common after introduction of amiodarone, and the
ituitary-thyroid axis normally stabilizes after 3 months (2). Details
re available in the Online Appendix. Approval was obtained from the
ocal ethics committee.
The IPAH patients on amiodarone were younger than CTEPH
nd CHD controls. They had a higher mean pulmonary artery
ressure compared with CTEPH (49  9 mm Hg vs. 41  13 mm
g, p  0.05), but not compared with CHD (54  24 mm Hg).
There were no differences in cardiac index, pulmonary vascular
resistance, or amiodarone exposure between IPAH and CTEPH
groups. Exposure to amiodarone was standardized to “200 mg/day/
year” units (dose-years). CHD patients had the greatest exposure to
amiodarone (3.8  2.6 dose-years vs. 2.4  2.5 dose-years [IPAH]
s. 1.5  1.4 dose-years [CTEPH], p  0.01).
Twelve of the 21 (57.1%) IPAHpatients on amiodarone developed
thyroid dysfunction, compared with 12 of 72 (16.7%) of IPAH
patients not on amiodarone (p  0.001).
The IPAH group treated with amiodarone was 3.4 (1.8 to 6.5)
times more likely to develop thyroid dysfunction than IPAH patients
not on amiodarone. The prevalence of AITD in IPAH was also
significantly elevated compared with the prevalence of AITD in
CTEPH (57.1% vs. 17.4%, p  0.01). The IPAH group on
amiodarone was 3.3 (1.3 to 8.6) times more likely to develop thyroid
dysfunction than CTEPH patients on amiodarone. Of the 12 IPAH
patients who developed AITD, 8 required hospitalization and 2 died.
One CHD and 2 CTEPH patients needed hospitalization, and there
were no deaths. oWe then compared the characteristics of all patients who developed
AITD with all patients who remained euthyroid (Fig. 1). There was
an overrepresentation of IPAH in AITD (64% vs. 20%, p  0.003).
There was a trend towards greater amiodarone exposure in all patients
who developed AITD compared with those that did not (2.6 vs. 1.7
dose-years, p  0.06). IPAH patients with AITD had a greater
exposure to amiodarone compared with IPAH patients on amioda-
rone who remained euthyroid (2.8 vs. 0.7 dose-years; p  0.008).
There was a trend towards significance in the equivalent CTEPH
groups (2.8 vs. 1.5 dose-years; p  0.08).
IPAH patients have a higher prevalence of thyroid disease than the
general population, estimated at 19% to 24% (3) compared with a
baseline of 2.5% to 9.5% (4). The exact reasons for this remain
unclear, but may be related to an autoimmune component in the
pathobiology of IPAH (5). Thyroid dysfunction is a well-known side
effect of amiodarone. However, we noted that the prevalence of
AITD in CTEPH was 17%, which is in keeping with the prevalence
of AITD in left heart disease. Therefore, we infer that the presence of
pulmonary hypertension per se does not increase the risk of AITD,
but rather the presence of idiopathic pulmonary hypertension.
This increase in AITD is also not simply attributable to prolonged
use of amiodarone in a predominantly female population; as the CHD
patients have a greater exposure but a lower prevalence of AITD. A
possible underlying explanation is that amiodarone is unmasking a
tendency towards autoimmune thyroid disease in IPAH. Amiodarone
can have a direct cytotoxic effect on thyroid follicular cells (6). This
ould release previously hidden antigens and may enable sensitization
o occur in vulnerable IPAH patients. Unfortunately, we were not able
o compare the type of autoantibodies present in the PAH cohorts as
nvestigation of thyroid disease was left to referring hospitals.
The main drawback of this study was its predominantly retrospec-
ive nature, which inevitably resulted in missing data. These were
lled by consulting referring physicians. The other problem lies in the
mall numbers, which is due to the rarity of these diseases and the
election of subgroups. After taking statistical advice, we have not
ttempted to perform multivariate analysis.
The other striking result is that in IPAH, the extent of exposure to
miodarone may matter. Should a true dose-dependent relationship
xist, strategies that could be implemented include avoiding amioda-
one altogether or resorting to amiodarone as a short-term measure,
rior to radiofrequency ablation. Should ablation prove impossible,
nother alternative to amiodarone would be its iodine-free derivative
ronedarone, which has very few thyroid side effects.
This investigation demonstrates that IPAH patients are particu-
arly susceptible to AITD, with potentially life-threatening conse-
uences. Prolonged exposure increases the risk. Chronic amiodarone
hould only be prescribed after careful consideration of all other
ptions. IPAH patients who are on amiodarone should have their
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they develop AITD.
Figure 1 Prevalence of Thyroid Diseaseand Associated Risk Factors in PAH
(A) Point prevalence of amiodarone-induced thyroid disease in all pulmonary arte-
rial hypertension (PAH) groups; and (B) comparison of PAH patients who devel-
oped amiodarone-induced thyroid dysfunction (AITD) and who remained euthyroid
on amiodarone. Data shown as mean (SD). CHD  congenital heart disease; CI 
cardiac index; CTEPH  chronic thromboembolic pulmonary hypertension; IPAH 
idiopathic pulmonary arterial hypertension; mPAP  mean pulmonary artery pres-
sure; PVR  pulmonary vascular resistance.Elaine Soon, MBBChir
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APPENDIX
For an expanded Methods section,
please see the online version of this article.
